Karim Fizazi, MD, PhD, on Prostate Cancer: Newly Reported Survival Rates With Abiraterone, Docetaxel, and Prednisone

September 22, 2021 By The ASCO Post Staff

Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, discusses phase III results from the PEACE-1 study, which showed that androgen-deprivation therapy plus docetaxel and abiraterone provided 2.5 years of additional time without radiographic disease progression or death and 1.5 additional years of survival in men with de novo high-volume metastatic castration-sensitive prostate cancer (Abstract LBA5).

Related Content